A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Key facts

Sponsor

Fondazione Italiana Linfomi - ETS

Principal Investigator

Alessandra Tucci, Dr.ssa

UO Ematologia, ASST Spedali Civili di Brescia, Piazzale Spedali Civili, 1, 25123 Brescia, Italia

Intervention

Rituximab + Golcadomide (CC-99282)(drug)

Enrollment

47 enrolled

Eligibility

80 years · All sexes

Timeline

2025 – 2030

Study locations (20)

• AOU SS. Antonio e Biagio e Cesare Arrigo di Alessandria - SCDU Ematologia, Alessandria, Italy
• AOU Ospedali Riuniti - Clinica di Ematologia, Ancona, Italy
• Azienda Ospedaliera S. Giuseppe Moscati - S.C. Ematologia e trapianto emopoietico, Avellino, Italy
• Ospedale IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuno-correlati, Aviano, Italy
• ASST Spedali Civili di Brescia - Ematologia, Brescia, Italy
• Azienda Ospedaliera Universitaria Careggi -Unità Funzionale di Ematologia, Florence, Italy
• ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia, Milan, Italy
• Fondazione IRCCS San Gerardo dei Tintori -Ematologia, Monza, Italy
• I.R.C.C.S. Istituto Oncologico Veneto -Oncologia 1, Padua, Italy
• Policlinico Giaccone - Ematologia, Palermo, Italy
• Azienda Sanitaria Locale di Pescara- Presidio Ospedaliero Santo Spirito - U.O.C. Ematologia, Pescara, Italy
• Azienda USL Piacenza - UOC Ematologia e Centro Trapianti,, Piacenza, Italy
• Ospedale delle Croci - Ematologia, Ravenna, Italy
• Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia, Reggio Emilia, Italy
• Ematologia - Trapianto cellule staminali - Medicina Trasfusionale e Terapie Cellulari, Policlinico Universitario Campus Bio-Medico, Roma, Italy
• +5 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for B-cell non-Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07133997
  Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
  City of Hope Medical Center
• RECRUITINGPHASE1NCT07361224
  Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.
  Tel-Aviv Sourasky Medical Center
• RECRUITINGPHASE2NCT07523737
  Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
  Beijing Tongren Hospital
• RECRUITINGPHASE1, PHASE2NCT07283679
  Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
  M.D. Anderson Cancer Center
• RECRUITINGPHASE1, PHASE2NCT07135466
  A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
  Sheba Medical Center
• ACTIVE NOT RECRUITINGPHASE2NCT07480850
  Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
  Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• ACTIVE NOT RECRUITINGNCT07480837
  Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma
  Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• RECRUITINGEARLY PHASE1NCT07376642
  A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
  Suzhou Immunofoco Biotechnology Co., Ltd

See all trials for B-cell non-Hodgkin lymphoma →